The estimated Net Worth of Brent Hatzis Schoch is at least $747 Mille dollars as of 12 May 2021. Mr Schoch owns over 4,078 units of Black Diamond Therapeutics Inc stock worth over $76,490 and over the last 9 years he sold BDTX stock worth over $0. In addition, he makes $670,233 as COO & Gen. Counsel at Black Diamond Therapeutics Inc.
Sign up
Mr D BDTX stock SEC Form 4 insiders trading
Mr has made over 11 trades of the Black Diamond Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 4,078 units of BDTX stock worth $13,050 on 12 May 2021.
The largest trade he's ever made was exercising 11,578 units of Black Diamond Therapeutics Inc stock on 12 January 2021 worth over $94,476. On average, Mr trades about 2,515 units every 64 days since 2016. As of 12 May 2021 he still owns at least 12,478 units of Black Diamond Therapeutics Inc stock.
You can see the complete history of Mr Schoch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Brent Hatzis-Schoch Esq., J.D. biography
Brent Hatzis-Schoch Esq., J.D. is the COO & Gen. Counsel at Black Diamond Therapeutics Inc.
What is the salary of Mr D?
As the COO & Gen. Counsel of Black Diamond Therapeutics Inc, the total compensation of Mr D at Black Diamond Therapeutics Inc is $670,233. There are 4 executives at Black Diamond Therapeutics Inc getting paid more, with David Epstein having the highest compensation of $3,346,080.
How old is Mr D?
Mr D is 56, he's been the COO & Gen. Counsel of Black Diamond Therapeutics Inc since . There are 8 older and 11 younger executives at Black Diamond Therapeutics Inc. The oldest executive at Black Diamond Therapeutics Inc is Robert Ingram, 77, who is the Independent Chairman of the Board.
What's Mr D's mailing address?
Brent's mailing address filed with the SEC is C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA, 02142.
Insiders trading at Black Diamond Therapeutics Inc
Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah e Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.
What does Black Diamond Therapeutics Inc do?
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
What does Black Diamond Therapeutics Inc's logo look like?
Complete history of Mr Schoch stock trades at Radius Recycling e Black Diamond Therapeutics Inc
Black Diamond Therapeutics Inc executives and stock owners
Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Epstein,
President, Chief Executive Officer, Director -
Thomas Leggett,
Chief Financial Officer -
Christopher Roberts,
Chief Scientific Officer -
Dr. David M. Epstein Ph.D.,
Co-Founder, Pres, CEO & Director -
Brent Hatzis-Schoch Esq., J.D.,
COO & Gen. Counsel -
Samarth Kulkarni,
Independent Director -
Dr. Rachel Wallach Humphrey M.D., Ph.D.,
Advisor -
Garry Menzel,
Independent Director -
Rajeev Shah,
Independent Director -
Ali Behbahani,
Independent Director -
Alexander Mayweg,
Director -
Bradley Bolzon,
Director -
Fang Ni,
Chief Business Officer -
Rachel Humphrey,
Chief Medical Officer -
Karsten Witt,
Senior Vice President - Non-Clinical Development -
Elizabeth Buck,
Executive Vice President - Discovery and Translational Services -
Brent Hatzis-Schoch,
Chief Operating Officer, General Counsel -
Robert Ingram,
Independent Chairman of the Board -
Tai-An Lin Ph.D.,
VP & Head of Biology -
Dr. Karsten Witt M.D.,
Sr. VP of Clinical Devel. & Interim Chief Medical Officer -
Dr. Christopher D. Roberts Ph.D.,
Advisor -
Erika Jones,
VP of Fin., Corp. Controller & Principal Accounting Officer -
Dr. Fang Ni Pharm.D.,
CFO, Principal Financial Officer and Chief Bus. Officer -
Dr. Elizabeth Buck Ph.D.,
Co-Founder & Chief Scientific Officer -
James E Deerfield Mgmt L.P....,
-
Sergey Yurasov,
CHIEF MEDICAL OFFICER -
Shannon Campbell,
-
Prakash Raman,
-
Venture Capital Vi, L.P.Ver...,
-
Biomedical Innovation Maste...,
10% owner -
Venture Capital Vi, L.P.Ver...,
-
Erika Jones,
SEE REMARKS -
Wendy L Dixon,
-
Growth N Vbb Biotech Ag Bio...,
-
Kapil Dhingra,
-
Capital Management, L.P.Ra ...,
-
Mark A. Velleca,
PRESIDENT & CEO